S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:NCNA

NuCana Stock Forecast, Price & News

$2.61
+0.01 (+0.38%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.50
$2.64
50-Day Range
$2.27
$2.86
52-Week Range
$1.88
$6.50
Volume
263,157 shs
Average Volume
253,624 shs
Market Capitalization
$136.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.66
30 days | 90 days | 365 days | Advanced Chart
Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.


NuCana logo

About NuCana

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Headlines

NuCana: Preparing For A Critical 2022 - Seeking Alpha
December 8, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NCNA
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.63 per share

Profitability

Net Income
$-39.40 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$136.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/17/2021
Today
1/28/2022
Next Earnings (Estimated)
3/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

908th out of 1,417 stocks

Pharmaceutical Preparations Industry

449th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












NuCana (NASDAQ:NCNA) Frequently Asked Questions

Is NuCana a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NuCana stock.
View analyst ratings for NuCana
or view top-rated stocks.

How has NuCana's stock been impacted by Coronavirus (COVID-19)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NCNA shares have decreased by 58.8% and is now trading at $2.61.
View which stocks have been most impacted by COVID-19
.

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for NuCana
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) issued its quarterly earnings data on Wednesday, November, 17th. The company reported ($15.00) earnings per share for the quarter, beating the Zacks' consensus estimate of ($18.50) by $3.50.
View NuCana's earnings history
.

What price target have analysts set for NCNA?

2 brokers have issued 1 year target prices for NuCana's shares. Their forecasts range from $9.00 to $9.00. On average, they expect NuCana's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for NuCana
or view top-rated stocks among Wall Street analysts.

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Hugh Stephen Griffith, Chief Executive Officer & Executive Director
  • Donald Munoz, Chief Financial Officer
  • Elisabeth Oelmann, Senior VP-Medical & Clinical Development
  • Jeffrey D. Bloss, Chief Medical Officer
  • Theresa Margaret Bruce, Senior Vice President-Clinical Operations

What other stocks do shareholders of NuCana own?

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $2.61.

How much money does NuCana make?

NuCana has a market capitalization of $136.14 million. The company earns $-39.40 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does NuCana have?

NuCana employs 2,020 workers across the globe.

What is NuCana's official website?

The official website for NuCana is www.nucana.com.

Where are NuCana's headquarters?

NuCana is headquartered at 3 Lochside Way, Edinburgh X0, EH12 9DT.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 441313571111 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.